QuickView for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=83E286E74EDD02FF9D8798CF638465E5;jsessionid=D7FFE99F12BF2E4EB7D38EBC69DA554B;jsessionid=36F903B008D559D25B0614918BC4DCE5;jsessionid=465606163BCE8F6E8A7CE02352D7D8E0;jsessionid=9EEF6C911AF1A5F08FED7386817B96CD;jsessionid=A659BD0D7A29FE1F5EBE0B96DF29FE90;jsessionid=4C4E8C5FF33DAE223A6A4D9B99968611;jsessionid=6034A64A4A66F46D4312E00E1FF77432;jsessionid=00402E6773041E2FFFA3E4197B77FFD1 (gene)

1. Biochemical characterization of mutants in chaperonin proteins CCT4 and CCT5 associated with heredit…
2. Role of CCT4/ErbB signaling in nephroblastoma: Implications for a biomarker of Wilms tumor.
3. Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair pro…
4. Transient Kinetic Analysis of ATP Hydrolysis by the CCT/TRiC Chaperonin.
5. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal sq…

There were no clinical trials for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=83E286E74EDD02FF9D8798CF638465E5;jsessionid=D7FFE99F12BF2E4EB7D38EBC69DA554B;jsessionid=36F903B008D559D25B0614918BC4DCE5;jsessionid=465606163BCE8F6E8A7CE02352D7D8E0;jsessionid=9EEF6C911AF1A5F08FED7386817B96CD;jsessionid=A659BD0D7A29FE1F5EBE0B96DF29FE90;jsessionid=4C4E8C5FF33DAE223A6A4D9B99968611;jsessionid=6034A64A4A66F46D4312E00E1FF77432;jsessionid=00402E6773041E2FFFA3E4197B77FFD1